GlassScriptPhysician profile
Cory R Tinker
NPI 1568493948
$1,353.99
in general payments reported to CMS, 2019-2025
25 companies · $416 in 2025
The $416 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.36 · 2022: $491 · 2023: $260 · 2024: $101 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $177.65 | 2022-2025 | Liletta, Orilissa, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $177.48 | 2022-2025 | |
| Astellas Pharma US INC | $176.11 | 2025 | Veozah |
| Bausch Health US, LLC | $128.74 | 2022-2024 | Aplenzin, Wellbutrin |
| Myovant Sciences INC. | $98.70 | 2022 | |
| Millicent US INC | $73.73 | 2023-2025 | Intrarosa, Femlyv |
| Pfizer INC. | $66.64 | 2022-2023 | |
| Coopersurgical, INC. | $43.77 | 2024 | Paragard T 380a |
| Therapeuticsmd, INC. | $39.82 | 2019-2022 | |
| Evofem Biosciences, INC. | $38.42 | 2022-2025 | Phexxi, Solosec, Phexx |
| Scynexis, INC. | $37.35 | 2022 | |
| Azurity Pharmaceuticals, INC. | $31.84 | 2023 | Adthyza |
| Minerva Surgical, INC | $30.68 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.34 | 2019-2025 | |
| Lupin INC. | $27.43 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $22.83 | 2024 | |
| Sage Therapeutics, LLC | $22.12 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $21.18 | 2023 | Myfembree |
| Meditrina | $17.28 | 2025 | |
| Mylan Pharmaceuticals INC. | $17.05 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.79 | 2019 | |
| Axonics, INC. | $15.44 | 2023 | Axonics |
| Exeltis, USA INC. | $14.86 | 2022 | |
| Shield Therapeutics INC | $14.71 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Tinker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.